Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Mallinckrodt
AstraZeneca
Johnson and Johnson
Express Scripts

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Claims for Patent: 5,756,733

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,756,733
Title: Vitamin D amide derivatives
Abstract:The invention relates to novel 1.alpha.-hydroxy vitamin D derivatives and their 20-epi analogues, comprising compounds of general formula (I) ##STR1## where R.sup.1 and R.sup.2, which may be the same or different, each represents a hydrogen atom or an aliphatic, cycloaliphatic, araliphatic or aryl group or together with the nitrogen atom to which they are attached form a heterocyclic group; R.sup.3 represents a methyl group having .alpha.- or .beta.-configuration; X represents a valence bond or a C.sub.1-2 alkylene group; Y represents --O--, --S--, --CH.sub.2 -- or --NR-- where R is a hydrogen atom or an organic group; Z represents a valence bond or a C.sub.1-3 alkylene group; and A.dbd. represents a cyclohexylidene moiety characteristic of the A-ring of a 1.alpha.-hydroxylated vitamin D or analogue thereof, with the proviso that when --X--Y--Z-- together represent an alkylene group containing up to 4 carbon atoms A.dbd. does not carry an exocyclic methylene group at the 10-position. Active compounds of the invention exhibit cell modulating activity while exhibiting a substantial lack of calcemic effect.
Inventor(s): Hesse; Robert Henry (Winchester, MA), Setty; Sundara Katugam Srinivasasetty (Cambridge, MA), Ramgopal; Malathi (Andover, MA)
Assignee: Research Institute for Medicine and Chemistry (Cambridge, MA)
Application Number:08/532,799
Patent Claims:1. A compound of the formula (I) ##STR10## where R.sup.1 and R.sup.2, which may be the same or different, each represent a hydrogen atom or an aliphatic, cycloaliphatic, araliphatic or aryl group or together with the nitrogen atom to which they are attached form a heterocyclic group; R.sup.3 represents a methyl group having .alpha.- or .beta.-configuration; X represents a valence bond or a C.sub.1-2 alkylene group; Y represents --O--, --S--, --CH.sub.2 -- or --NR-- where R is a hydrogen atom or an organic group; Z represents a valence bond or a C.sub.1-3 alkylene group; and A.dbd. represents a cyclohexylidene moiety characteristic of the A-ring of a 1.alpha.-hydroxylated vitamin D or analogue thereof, with the proviso that when --X--Y--Z-- together represent an alkylene group containing up to 4 carbon atoms A.dbd. does not carry an exocyclic methylene group at the 10-position.

2. Compounds of general formula (I) as claimed in claim 1 wherein A.dbd. represents one of the groups ##STR11## (where R.sup.4 and R.sup.5, which may be the same or different, each represent a hydrogen atom or an O-protecting group).

3. Compounds of general formula (I) as claimed in claim 2 wherein R.sup.4 and R.sup.5 represent etherifying silyl groups.

4. Compounds of general formula (I) as claimed in claim 2 wherein R.sup.4 and R.sup.5 are selected from hydrogen atoms and metabolically labile etherifying or esterifying groups.

5. Compounds of general formula (I) as claimed in claim 1 wherein A.dbd. represents one of the groups ##STR12##

6. Compounds of general formula (I) as claimed in claim 1 wherein R.sup.1 and R.sup.2 are selected from hydrogen atoms, C.sub.1-6 alkyl groups, C.sub.3-8 cycloalkyl groups, C.sub.6-12 aryl C.sub.1-4 alkyl and optionally substituted C.sub.6-12 carbocyclic aryl groups.

7. Compounds of general formula (I) as claimed in claim 6 wherein R.sup.1 and R.sup.2 are selected from hydrogen atoms, C.sub.1-6 alkyl groups and C.sub.3-8 cycloalkyl groups.

8. Compounds of general formula (I) as claimed in claim 7 wherein R.sup.1 and R.sup.2 are selected from hydrogen atoms, methyl, ethyl and cyclopropyl groups.

9. Compounds of general formula (I) as claimed in claim 1 wherein R.sup.1 R.sup.2 N-- represents a heterocyclic group comprising one or more 5- and/or 6-membered rings optionally containing one or more further heteroatoms selected from O, N and S.

10. Compounds of general formula (I) as claimed in claim 9 wherein R.sup.1 R.sup.2 N-- represents a piperidino group.

11. The use of an active compound of general formula (I) as claimed in claim 1 for the manufacture of a medicament for use in wound healing, suppression of parathyroid hormone or in the treatment or prophylaxis of neoplastic disease, infection, bone disease, autoimmune disease, host-graft reaction, transplant rejection, inflammatory disease, neoplasia, hyperplasia, myopathy, enteropathy, spondylitic heart disease, dermatological disease, hypertension, rheumatoid arthritis, psoriatic arthritis, secondary hyperparathyroidism or asthma in a human or animal subject.

12. Pharmaceutical compositions comprising an active compound of general formula (I) as claimed in claim 1 in admixture with one or more physiologically acceptable carriers or excipients.

13. A method of treatment of a human or animal subject to promote wound healing or suppression of parathyroid hormone or to combat neoplastic disease, infection, bone disease, autoimmune disease, host-graft reaction, transplant rejection, inflammatory disease, neoplasia, hyperplasia, myopathy, enteropathy, spondylitic heart disease, dermatological disease, hypertension, rheumatoid arthritis, psoriatic arthritis, secondary hyperparathyroidism or asthma, comprising administration to said subject of an effective amount of an active compound of general formula (I) as claimed in claim 1.

14. A process for the preparation of a compound of general formula (I) as defined in claim 1 which comprises either:

A) isomerising a 5,6-trans isomer of general formula (I) to a corresponding 5,6-cis isomer, followed if necessary and/or desired by removal of any O-protecting groups;

B) hydroxylating a 1-unsubstituted-5,6-trans analogue of a compound of general formula (I) to prepare a 5,6-trans isomer of general formula (I), followed if necessary and/or desired by isomerisation and/or removal of any O-protecting group;

C) reacting a compound containing a precursor for the desired 17-position side chain in one or more stages and with one or more reactants serving to form the desired side chain, followed if necessary and/or desired by isomerisation and/or removal of any O-protecting groups; or

D) reacting a compound of formula (I) to modify the substitution pattern about the A.dbd. group, followed if necessary and/or desired by isomerisation and/or removal of protecting groups.

Summary for Patent:   See Pricing

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9309422May 7, 1993
PCT Information
PCT FiledMay 06, 1994PCT Application Number:PCT/GB94/00975
PCT Publication Date:November 24, 1994PCT Publication Number:WO94/26707

Details for Patent 5,756,733

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23   See Pricing Research Institute for Medicine and Chemistry (Cambridge, MA) 2013-05-07 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23   See Pricing Research Institute for Medicine and Chemistry (Cambridge, MA) 2013-05-07 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23   See Pricing Research Institute for Medicine and Chemistry (Cambridge, MA) 2013-05-07 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23   See Pricing Research Institute for Medicine and Chemistry (Cambridge, MA) 2013-05-07 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Harvard Business School
Johnson and Johnson
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.